Details
Category: Volume 07 Issue 12 December 2019
Hits: 1081

Title: Trimetazidine in Stable angina pectoris and Type 2 Diabetes Mellitus: Safety & Effectiveness: A Descriptive study

Authors: Dr Rajiv Girdhar, Dr Ram Chaitanya Kothapalli, Dr Nareshchand Hegde H, Dr Aashish D Rayapati

 DOI: https://dx.doi.org/10.18535/jmscr/v7i12.112

Abstract

An observational, non interventional, open-label clinical study assessed the effectiveness/safety of trimetazidine in 101 patients with stable angina pectoris and Type 2 diabetes mellitus.

Results: Trimetazidine-based therapy was effective in stable coronary artery disease, with significant improvements from baseline (p < 0.05) in: number of angina attacks/week (2.9 ± 2.4 vs 1.1 ± 1.6), angina severity (Canadian Cardiovascular Society Classification 1.9 ± 0.8 vs 1.2 ± 0.8), exercise capacity (metabolic equivalents 6.8 ± 1.7 vs 6.5 ± 1.7), and exercise-induced myocardial ischemia (min 5.5 ± 2.5 vs 6.5 ± 2.6).

Discussion: Trimetazidine treatment significantly (p < 0.05) improved glucose metabolism, lowered HbA1c (7.1 ± 1.1% vs 6.6 ± 1.0%), glucose levels (7.7 ± 2.1 mmol/l vs 6.9 ± 1.6 mmol/l) and decreased arterial stiffness (pulse wave velocity 11.2 ± 2.1 m/s vs 10.4 ± 2.2 m/s). In most patients, the tolerability of trimetazidine was rated as excellent to good, with a low incidence of adverse events.

Keywords: stable coronary artery disease • trimetazidine • Type 2 diabetes mellitus.

References

  1. Aksoyek 1996 {published data only} Aksoyek S, Kabukcu M, Ovunc K, Kabakci G, Aytemir K, Oto A. Clinical efficacy of trimetazidine instable angina pectoris: A doubleblind placebo controlled study [Kararli angina pektoriste trimetazidine’in klinik etkinligi: cift kor, plasebo kontrollu calisma]. Turk Kardiyoloji Dernegi Arsivi 1996;24 (5):261-2+289-92.
  2. Bermudez-HT 1995 {published data only} Bermúdez Arias F, Baptista Arrieta G, Fernández A, Madrid L, Colmenares R, García F, et al. First american study of trimetazidine (FAST) [Primer estudio americano de trimetazidine (FAST)]. Archivos Venezolanos de Farmacología y Terapéutica 1995;14(1):39– 53.
  3. Bermudez-NT 1995 {published data only} Bermúdez Arias F, Baptista Arrieta G, Fernández A, Madrid L, Colmenares R, García F, et al. First american study of trimetazidine (FAST) [Primer estudio americano de trimetazidine (FAST)]. Archivos Venezolanos de Farmacología y Terapéutica 1995;14(1):39– 53.
  4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16(2), 434–444 (1993).
  5. Padial LR. Clinical benefits of trimetazidine in patients with coronary artery disease and diabetes mellitus. Heart Metab. 45, 26–29 (2009).
  6. Canadian Cardiovascular Society. Angina classification scale. www.ccs.ca/en/.
  7. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomized controlled trials in heart failure. Heart 97(4), 278–286 (2011).
  8. Fragasso G, Rosano G, Baek SH et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int. J. Cardiol. 163(3), 320–325 (2013).
  9. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 86(5), 580–588 (2000) .
  10. Fragasso G, Piatti PM, Monti L et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am. Heart J. 146(5), e18 (2003).
  11. Monti LD, Setola E, Fragasso G et al. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with Type 2 diabetes and ischemic cardiomyopathy. Am. J. Physiol. Endocrinol. Metab. 290(1), E54–E59 (2006)
  12. Guarnieri C, Muscari C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle. Cardiovasc. Drugs Ther. 4(Suppl. 4), 814–815 (1990).
  13. Coetzee WA, Enous R, Opie LH. Trimetazidine: effects on delayed after depolarizations (DADs) and upstroke velocity of the action potential. Cardiovasc. Drugs Ther. 4(Suppl. 4), 806–807 (1990).
  14. Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology 46(6), 324–331 (1993).
  15. Tritto I, Wang P, Kuppusamy P, Giraldez R, Zweier JL, Ambrosio G. The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury. J. Cardiovasc. Pharmacol. 46(1), 89–98 (2005).
  16. Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch. Int. Pharmacodyn. Ther. 286(1), 97–110 (1987).
  17. Lagadic-Gossmann D, Le Prigent K, Feuvray D. Effects of trimetazidine on pH regulation in the rat isolated ventricular myocyte. Br. J. Pharmacol. 117(5), 831–838 (1996).
  18. Belardinelli R, Solenghi M, Volpe L, Purcaro A. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur. Heart J. 28(9), 1102–1108 (2007).
  19. Vitale C, Marazzi G, Pelliccia F et al. Trimetazidine improves exercise performance in patients with peripheral arterial disease. Pharmacol. Res. 63(4), 278–283 (2011).
  20. Lenkey Z, Illyes M, B ´ ocskei R ¨ et al. Comparison of arterial stiffness parameters in patients with coronary artery disease and diabetes mellitus using Arteriograph. Physiol. Res. 63(4), 429–437 (2014).
  21. Lacy PS, O’Brien DG, Stanley AG, Dewar MM, Swales PP, Williams B. Increased pulse wave velocity is not associated with elevated augmentation index in patients with diabetes. J. Hypertens. 22(10), 1937–1944 (2004).
  22. Westerbacka J, Uosukainen A, Makimattila S, Schlenzka A, Yki-J ¨ arvinen H. Insulin-induced decrease in large artery stiffness is impaired ¨ in uncomplicated type 1 diabetes mellitus. Hypertension 35(5), 1043–1048 (2000).
  23. Zhou X, Chen J. Is treatment with trimetazidine beneficial in patients with chronic heart failure? PLoS ONE 9(5), e94660 (2014).
  24. Ambrosio G, Komajda M, Mugelli A, Lopez-Sendon J, Tamargo J, Camm J. Management of stable angina: a commentary on the ´ European Society of Cardiology guidelines. Eur. J. Prev. Cardiol. 23(13), 1401–1412 (2016).
  25. Manolis AJ, Poulimenos LE, Ambrosio G et al. Medical treatment of stable angina: a tailored therapeutic approach. Int. J. Cardiol. 220, 445–453 (2016).

Corresponding Author

Dr Rajiv Girdhar